These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38113419)

  • 1. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
    Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
    J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
    Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
    Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
    Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
    Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
    Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital spatial profiling of CD4
    Takeuchi M; Miyoshi H; Semba Y; Yamada K; Nakashima K; Sato K; Furuta T; Moritsubo M; Ogura Y; Tanaka K; Imamoto T; Arakawa F; Kohno K; Ohshima K
    Virchows Arch; 2023 Aug; 483(2):255-260. PubMed ID: 37270432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
    Nagpal P; Descalzi-Montoya DB; Lodhi N
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 11. Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.
    Perry AM; Smith LB; Bagg A
    Acta Med Acad; 2021 Apr; 50(1):110-125. PubMed ID: 34075767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
    Jachimowicz RD; Pieper L; Reinke S; Gontarewicz A; Plütschow A; Haverkamp H; Frauenfeld L; Fend F; Overkamp M; Jochims F; Thorns C; Leo Hansmann M; Möller P; Rosenwald A; Stein H; Reinhardt HC; Borchmann P; von Tresckow B; Engert A; Klapper W
    Haematologica; 2021 Jun; 106(6):1684-1692. PubMed ID: 32381573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass cytometry of Hodgkin lymphoma reveals a CD4
    Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
    Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.
    Zhang C; Deng J; Xie Y; Mi L; Liu W; Wang X; Zhao L; Song Y; Zhu J
    Cancer Med; 2023 May; 12(9):10351-10362. PubMed ID: 37081731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
    Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
    Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
    Le-Nguyen A; Rys RN; Petrogiannis-Haliotis T; Johnson NA
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1432. PubMed ID: 34047076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
    Khurana A; Armand P; Ansell SM
    Leuk Lymphoma; 2020 May; 61(5):1063-1074. PubMed ID: 31914840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
    Chan FC; Mottok A; Gerrie AS; Power M; Nijland M; Diepstra A; van den Berg A; Kamper P; d'Amore F; d'Amore AL; Hamilton-Dutoit S; Savage KJ; Shah SP; Connors JM; Gascoyne RD; Scott DW; Steidl C
    J Clin Oncol; 2017 Nov; 35(32):3722-3733. PubMed ID: 28898161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
    J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.